Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Portfolio Pulse from Benzinga Insights
Roivant Sciences (NASDAQ:ROIV) has been analyzed by 6 analysts in the last three months, all of whom have given bullish ratings. The average 12-month price target is $18.33, reflecting a 12.8% increase from the previous average. Analysts have maintained or raised their price targets, indicating positive sentiment. Despite this, the company faces challenges with below-industry benchmarks in net margin, ROE, and ROA.
June 18, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roivant Sciences has received bullish ratings from 6 analysts, with an average 12-month price target of $18.33, reflecting a 12.8% increase. Analysts have either maintained or raised their price targets, indicating positive sentiment. However, the company faces challenges with below-industry benchmarks in net margin, ROE, and ROA.
The unanimous bullish ratings and increased price targets from analysts suggest a positive short-term impact on ROIV's stock price. However, the company's financial challenges in profitability and returns may temper long-term expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100